[199 Pages Report] The Human Antimicrobial Susceptibility Testing Market size was estimated at USD 3.71 billion in 2023 and expected to reach USD 3.92 billion in 2024, at a CAGR 5.88% to reach USD 5.54 billion by 2030.
The human antimicrobial susceptibility testing (AST) market encompasses the range of diagnostic processes and products employed to determine the susceptibility of specific microbial organisms, including bacteria and fungi, to various antimicrobial agents. This testing is crucial in guiding the appropriate selection of antimicrobial therapy for individual patients, optimizing clinical outcomes, and mitigating the risk of resistance development. The rising prevalence of bacterial and fungal infections globally fuels the demand for effective diagnostic testing such as AST. The growing problem of resistance to existing antibiotics underscores the need for AST to tailor treatments and develop new antimicrobials. However, the cost and complexity of advanced AST systems may limit accessibility, particularly in low-resource settings. Moreover, rising healthcare infrastructure and increasing awareness about infectious diseases in regions present significant growth opportunities. Development of portable, easy-to-use AST systems for use in outpatient settings or remote areas. Along with these, employing AI to predict susceptibility and resistance patterns could streamline AST processes, enhance predictive accuracy, and create new growth opportunities for the market.
Type: Rising R&D investment to develop next generation susceptibility testing
Antibacterial susceptibility testing involves the evaluation of bacterial pathogens against a range of antibacterial agents to identify effective treatment options. Antibacterial susceptibility testing addresses the growing concern over bacterial antibiotic resistance, a pressing public health issue. Techniques employed in antibacterial testing vary from traditional methods, such as disk diffusion and broth dilution tests, to more advanced molecular diagnostics and automated systems, offering scalability and efficiency in identifying antibacterial resistance. Antifungal susceptibility testing has gained prominence due to the rising incidence of fungal infections, particularly among immunocompromised individuals. This segment focuses on assessing the effectiveness of antifungal agents against yeasts and molds. The critical nature of fungal infections, the limited arsenal of antifungal medications, and the emergence of resistant strains underscores the importance of accurate and timely susceptibility testing. Techniques in this category aim to determine the minimal inhibitory concentrations (MICs) that can predict the therapeutic success of antifungal treatments. Antiparasitic susceptibility testing addresses the susceptibility of parasites to various antiparasitic drugs. This testing is crucial for diseases caused by protozoa and helminths, such as malaria, leishmaniasis, and soil-transmitted helminthiasis. Given the global burden of parasitic diseases, particularly in tropical and subtropical regions, and the challenge of drug resistance, the demand for effective antiparasitic susceptibility testing methodologies is evident. Antiparasitic susceptibility testing involves in vivo and in vitro methods to screen for effective antiparasitic agents, although challenges remain in standardizing and automating these tests for broader applications.
End User: Rising demand across hospital & diagnostic centers to guide patient-specific treatment strategies
CROs support the pharmaceutical, biotechnology, and medical device industries through research services outsourced on a contract basis. In human antimicrobial susceptibility testing, CROs often undertake studies that help assess the efficacy of new antimicrobial agents across varied microbial strains. This encompasses standard and more nuanced, custom-designed AST studies tailored to specific investigational needs. The insights generated through these studies are pivotal for advancing the research and development pipeline, especially in early-stage drug development, where understanding the potential effectiveness of new compounds is critical. Hospital and diagnostic centers represent an essential frontline for the utilization of human antimicrobial susceptibility testing. AST is a diagnostic tool in these settings to guide patient-specific treatment strategies. By identifying the most effective antimicrobial agents for a particular infection, clinicians can tailor treatments to individual patients, thereby improving patient outcomes and contributing to the broader effort to mitigate antimicrobial resistance. Furthermore, data collected from these settings can provide valuable epidemiological insights into drug resistance trends, guiding local and global health strategies. Within the pharmaceutical and biotechnology industries, antimicrobial susceptibility testing is integral to the lifecycle of new drugs, from discovery through to post-market surveillance. In the drug development phase, AST is used to evaluate the efficacy of new antimicrobial agents, facilitating the identification of promising candidates for further development. Beyond the research and development phase, these companies also utilize AST in pharmacodynamics studies and to support regulatory submissions. Moreover, post-approval, AST continues to be important for monitoring emerging resistance patterns and ensuring the ongoing effectiveness of antimicrobial agents. Research and academic institutes are often at the forefront of foundational and exploratory studies on antimicrobial susceptibility and resistance mechanisms. These entities focus on the basic science underpinning antimicrobial resistance and applying this knowledge to develop innovative solutions. Studies in these settings may encompass a wide range of focuses, from molecular resistance mechanisms to environmental factors’ impact on antimicrobial effectiveness. The work conducted within research and academic institutes is crucial for informing all other segments, offering a bedrock of scientific understanding upon which applied research and clinical strategies are built.
Regional Insights
In the Americas, the United States holds a significant portion of the market due to its well-established healthcare infrastructure and high awareness regarding AMR. The region strongly emphasizes research and development, leading to the adoption of advanced AST technologies such as automated systems and genotypic methods. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) play a crucial role in approving and overseeing AST products, ensuring their efficacy and safety. The EMEA region presents a diverse AST market due to varying levels of economic development, healthcare infrastructure, and regulatory frameworks. Europe is among the significant areas of adopting advanced AST methods, supported by strong regulatory standards set by the European Medicines Agency (EMA) and national bodies. The region is also at the forefront of addressing AMR through comprehensive antimicrobial stewardship programs. The Middle East shows a growing demand for AST due to rising AMR awareness and healthcare investments, particularly in Gulf Cooperation Council (GCC) countries. APAC is witnessing rapid growth in the AST market, fueled by increasing healthcare expenditures and rising awareness of AMR in countries such as China and India. The region benefits from local manufacturing of AST products, reducing costs and enhancing access. However, the vast diversity in economic and healthcare development levels across the region results in varied adoption rates of AST technologies.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Human Antimicrobial Susceptibility Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Antimicrobial Susceptibility Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Human Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE TIBBI MALZ, BioM?rieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, ELITech Group SAS, Erba Lachema s.r.o., F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Liofilchem S.r.l., Mast Group Ltd., Merck KGaA, Pfizer Inc., Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..
Market Segmentation & Coverage
This research report categorizes the Human Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type
- Antibacterial Susceptibility Testing
- Antifungal Susceptibility Testing
- Antiparasitic Susceptibility Testing
- Product
- Automated Laboratory Instruments
- Consumables
- Culture & Growth Media
- Manual Antimicrobial Susceptibility Testing Products
- Method
- Agar Dilution
- Automated Susceptibility Testing Instruments
- Disk Diffusion
- Etest Method
- Genotyping Methods
- Application
- Clinical Diagnostics
- Drug Discovery & Development
- Epidemiology
- End User
- Contract Research Organizations
- Hospital & Diagnostic Centers
- Pharmaceutical & Biotechnology
- Research & Academic Institutes
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Human Antimicrobial Susceptibility Testing Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Antimicrobial Susceptibility Testing Market?
- What are the technology trends and regulatory frameworks in the Human Antimicrobial Susceptibility Testing Market?
- What is the market share of the leading vendors in the Human Antimicrobial Susceptibility Testing Market?
- Which modes and strategic moves are suitable for entering the Human Antimicrobial Susceptibility Testing Market?
US $
Euro €
GBP £